GlaxoSmithKline’s (GSK) former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.

Former GSK CEO Sir Andrew Witty, and his former drug development chief, Moncef Slaoui have both lined up new jobs as life science investors. The announcements yesterday are part of a growing trend ...

executive Andrew Witty ... the big drugmaker GlaxoSmithKline for nearly a decade before joining UnitedHealth Group’s management team to run Optum before being elevated to CEO of UnitedHealth.

(Reuters) -UnitedHealth CEO Andrew Witty said on Thursday that healthcare ... who was previously CEO of British drugmaker GlaxoSmithKline. UnitedHealth, which operates the biggest health insurer ...

Mr. Wichmann was succeeded by Andrew Witty, the company's president. Mr. Witty, the 56-year-old former CEO of the drugmaker GlaxoSmithKline PLC, became the chief executive of UnitedHealth's Optum ...

UnitedHealth UNH.N CEO Andrew Witty said on Thursday that healthcare ... who was previously CEO of British drugmaker GlaxoSmithKline GSK.L. Drug costs:FTC report shows $7.3 billion in drug ...

(Reuters) -UnitedHealth CEO Andrew Witty said on Thursday that healthcare ... who was previously CEO of British drugmaker GlaxoSmithKline (NYSE:GSK). UnitedHealth (NYSE:UNH), which operates ...

(Reuters) -UnitedHealth CEO Andrew Witty said on Thursday that healthcare in the ... who was previously CEO of British drugmaker GlaxoSmithKline. UnitedHealth, which operates the biggest health ...

The big picture: UnitedHealth Group CEO Andrew Witty spoke at length Thursday about ... The intrigue: Witty is a former CEO of British drug company GSK. During his tenure there, he told CNBC ...